Results 81 to 90 of about 42,547 (218)

The Power of Hematopoietic Stem Cell Transplantation (HSCT): A Curative Approach for Diffuse Large B‐Cell Lymphoma (DLBCL) Incidentally Detected in a SCID Baby

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Lymphoma is a rare complication of X‐linked severe combined immunodeficiency (X‐SCID) caused by IL2RG deficiency. We report an infant with IL2RG‐SCID who developed diffuse large B‐cell lymphoma (DLBCL) during pretransplant evaluation. A male infant with T−B+ SCID was diagnosed at 1 month of age and referred for hematopoietic stem cell ...
Burcu Sarıgül Cimi   +15 more
wiley   +1 more source

Comparative Population Genomics Analysis of the Mammalian Fungal Pathogen Pneumocystis

open access: yesmBio, 2018
Pneumocystis species are opportunistic mammalian pathogens that cause severe pneumonia in immunocompromised individuals. These fungi are highly host specific and uncultivable in vitro.
Ousmane H. Cissé   +15 more
doaj   +1 more source

Cytomegalovirus in Bronchoalveolar Lavage Fluid: A Predictor of Outcome in Immunocompromised Patients

open access: yesJournal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Cytomegalovirus (CMV) is a prevalent herpesvirus that remains typically asymptomatic in immunocompetent individuals but can cause severe, potentially life‐threatening disease in immunocompromised patients. This study assessed the impact of CMV‐associated lower respiratory tract infections (LRTIs), diagnosed by polymerase chain reaction (PCR ...
Theodora Zouvani   +10 more
wiley   +1 more source

All‐Oral PI3Kδ and HDAC Inhibition with Parsaclisib Plus Chidamide and Step‐Down Maintenance in Relapsed or Refractory Peripheral T‐Cell Lymphoma: A Phase Ib Trial

open access: yesMedComm, Volume 7, Issue 10, October 2026.
ABSTRACT Single‐agent targeted therapies for relapsed or refractory peripheral T‐cell lymphoma (R/R peripheral T‐cell lymphoma [PTCL]) produce modest, short‐lived responses, underscoring the need for tolerable, chemotherapy‐free combinations. In an open‐label, single‐arm Phase Ib trial at two tertiary hospitals, we evaluated parsaclisib plus chidamide ...
Xufeng Luo   +21 more
wiley   +1 more source

Pneumocystis carinii -prevalenssi kaatopaikan rottapopulaatiossa

open access: yes, 2003
Pneumocystis carinii kuuluu sieniin muodostaen hyvin heterogeenisen ja isäntälajispesifisen ryhmän. Organismin eri tyyppejä tavataan ihmisillä ja useilla eri eläinlajeilla. P.
Dillard, Kati
core  

Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions [PDF]

open access: yes, 2010
Jose G Castro1, Maya Morrison-Bryant21Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA; 2Jackson Memorial Hospital/University of Miami Infectious Diseases Fellowship Program, Miami, Florida, USAAbstract:
null Morrison-Bryant   +5 more
core   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao   +5 more
wiley   +1 more source

Human Immmunodeficiency Virus Infection Related Pneumocystis Jiroveci Pneumonia and Suicide: An Autopsy Case Report

open access: yes, 2016
Pneumocystis jiroveci is the most common and serious opportunistic infection in acquired immune deficiency syndrome patients. It is detected in approximately 80% of human immunodeficiency virus (HIV) infected individuals. In this paper, we present a case
Muzaffer Yıldırım   +8 more
core   +1 more source

Real‐Life Study on Gilteritinib‐Related Infections (GilteRInf): An Italian SEIFEM Study

open access: yes
American Journal of Hematology, Volume 101, Issue 10, Page 2672-2676, October 2026.
Elisa Buzzatti   +25 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

open access: yesMedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Home - About - Disclaimer - Privacy